Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Novartis psoriasis drug secukinumab was superior to Amgen's Enbrel in a late-stage study, the Swiss company said on Monday, putting it in line to become the first of a clutch of new treatments to gain market approval.
A phase III trial involving 1,307 patients showed that secukinumab was more effective than Enbrel in clearing skin in patients with moderate to severe plaque-type psoriasis, a painful and unsightly skin condition that causes itching and scaling.
http://www.reuters.com/article/2013/07/08/novartis-psoriasis-idUSL6N0FE1Y820130708
A phase III trial involving 1,307 patients showed that secukinumab was more effective than Enbrel in clearing skin in patients with moderate to severe plaque-type psoriasis, a painful and unsightly skin condition that causes itching and scaling.
http://www.reuters.com/article/2013/07/08/novartis-psoriasis-idUSL6N0FE1Y820130708